Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Gene therapy company bluebird bio acquires Precision Genome Engineering

Executive Summary

Bluebird bio Inc. (gene therapy for genetic and orphan diseases) acquired Precision Genome Engineering Inc. (aka Pregenen; gene editing and cell signaling technologies) for 408.7k bluebird shares up front plus 94.1k shares held back for 18 months (together worth $19.2mm), and the assumption of $4.9mm of current liabilities.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies

UsernamePublicRestriction

Register